Literature DB >> 8562489

A case against subtyping in schizophrenia.

T E Goldberg1, D R Weinberger.   

Abstract

In this paper we consider the generally accepted view that schizophrenia is 'heterogeneous'. We point out that the view derives from prima facie evidence from clinical presentation, studies of course, and factor analysis. However, upon closer examination internal contradictions are apparent, e.g., subtypes change, different groupings of symptoms cooccur in the same individual. Another type of paradigm, depending on careful study of case controls (e.g., monozygotic twins discordant for schizophrenia) and distributions, indicates that abnormalities in neurocognition, regional cerebral blood flow, and regional neuroanatomy may be present in nearly every patient, irrespective of absolute level or diagnostic subtype. These results suggest that a simple model in which patients vary along a severity dimension might parsimoniously explain much of the variance. Thus, while it is possible and even probable that schizophrenia may have many etiologies, phenocopies may represent the expression of a unitary pathogenesis of greater or lesser impact.

Entities:  

Mesh:

Year:  1995        PMID: 8562489     DOI: 10.1016/0920-9964(95)00060-y

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  10 in total

Review 1.  Profiles of neuropsychologic function in schizophrenia.

Authors:  J Daniel Ragland
Journal:  Curr Psychiatry Rep       Date:  2003-08       Impact factor: 5.285

Review 2.  [Genetic and pharmacological effects on prefrontal cortical function in schizophrenia].

Authors:  Andreas Heinz; Dieter F Braus; Berenice Romero; Jürgen Gallinat; Imke Puls; Georg Juckel; Daniel R Weinberger
Journal:  Nervenarzt       Date:  2004-09       Impact factor: 1.214

3.  Automated classification of fMRI during cognitive control identifies more severely disorganized subjects with schizophrenia.

Authors:  Jong H Yoon; Danh V Nguyen; Lindsey M McVay; Paul Deramo; Michael J Minzenberg; J Daniel Ragland; Tara Niendham; Marjorie Solomon; Cameron S Carter
Journal:  Schizophr Res       Date:  2012-01-25       Impact factor: 4.939

Review 4.  [Deconstructing schizophrenia. Dimensional models or division into subtypes?].

Authors:  M Jäger; K Frasch; F U Lang; T Becker
Journal:  Nervenarzt       Date:  2012-03       Impact factor: 1.214

5.  Some thoughts on understanding why we don't better understand schizophrenia.

Authors:  R T Pivik
Journal:  J Psychiatry Neurosci       Date:  1996-03       Impact factor: 6.186

6.  Attacking Heterogeneity in Schizophrenia by Deriving Clinical Subgroups From Widely Available Symptom Data.

Authors:  Dwight Dickinson; Danielle N Pratt; Evan J Giangrande; MeiLin Grunnagle; Jennifer Orel; Daniel R Weinberger; Joseph H Callicott; Karen F Berman
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

7.  Neuropsychological profiles delineate distinct profiles of schizophrenia, an interaction between memory and executive function, and uneven distribution of clinical subtypes.

Authors:  S Kristian Hill; J Daniel Ragland; Ruben C Gur; Raquel E Gur
Journal:  J Clin Exp Neuropsychol       Date:  2002-09       Impact factor: 2.475

8.  Using latent class growth analysis to form trajectories of premorbid adjustment in schizophrenia.

Authors:  Veronica T Cole; José A Apud; Daniel R Weinberger; Dwight Dickinson
Journal:  J Abnorm Psychol       Date:  2012-01-16

9.  Deviant cortical sulcation related to schizophrenia and cognitive deficits in the second trimester.

Authors:  Michael Lloyd MacKinley; Priyadharshini Sabesan; Lena Palaniyappan
Journal:  Transl Neurosci       Date:  2020-07-15       Impact factor: 1.757

10.  Brain structure and function correlates of cognitive subtypes in schizophrenia.

Authors:  Daniel Geisler; Esther Walton; Melissa Naylor; Veit Roessner; Kelvin O Lim; S Charles Schulz; Randy L Gollub; Vince D Calhoun; Scott R Sponheim; Stefan Ehrlich
Journal:  Psychiatry Res       Date:  2015-08-21       Impact factor: 3.222

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.